HRMY

Harmony Biosciences Holdings, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-24

Figures on this page computed 2026-11-08 13:22 UTC

Last close

34.42USD

Market data, 2026-11-04

HRMY: weekly closes from 30.09 on 2026-05-15 to 34.42 on 2026-11-04, a move of +14.4%. Prices in USD.

Weekly closes, 2026-05-15 to 2026-11-04

Over that span: +14.4%

Except where said otherwise: 10-K for 2025, filed 2026-02-24

12.0xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
53.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
18.3%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
40.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
0.19Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

5 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.98x

3.02x

3.06x

0.87x

0.94x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-24

Sales1.98x
Its own average over 7 years, 439.2M.
Profit3.02x
Its own average over 8 years, 52.5M.
Free cash flow3.06x
Its own average over 8 years, 113.7M.
Debt0.87x
Its own average over 8 years, 194.1M.
Price0.94x
Its own average over 7 years, 37. Market data, 2026-11-04

Free cash flow is furthest from its own average, at 3.06 times.

The filed years, as a table

Each line is 100 at 2018-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2018-12-31	n/a	100.0
2019-12-31	100.0	15.8
2020-12-31	2,664.6	52.3
2021-12-31	5,094.9	120.2
2022-12-31	7,303.7	124.1
2023-12-31	9,708.5	122.6
2024-12-31	11,922.2	117.5
2025-12-31	14,486.3	118.9

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001104659-26-018859
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001104659-26-018859
Reported in: USD

The filing itself

Figures behind the shape

Growth

40.3%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate40.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income9.1%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

53.6%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capital53.6%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
Return on equity18.2%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
Return on assets12.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself

Margins

77.2%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin77.2%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Operating margin24.0%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Net margin18.3%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Free cash flow margin40.1%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself

Price

12.0x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings12.0x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
Price to book2.2x10-Q for 2025, filed 2026-11-04
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001104659-26-122390
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-11-04
- computed
- 10-K for 2025, filed 2026-02-24
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-02-24
The filing itself
Price to sales ratio2.2x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself

Safety

0.19

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.19
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-Q for 2025, filed 2026-11-04
The filing itself
Current ratio3.6010-Q for 2025, filed 2026-11-04
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001104659-26-122390
Reported in
USD
- 10-Q for 2025, filed 2026-11-04
- 10-Q for 2025, filed 2026-11-04
The filing itself
Interest coverage14.2x
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Altman Z-Score4.92
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001104659-26-018859
Reported in
USD
- 10-K for 2025, filed 2026-02-24
- Computed from the 10-K for 2025, filed 2026-02-24
- 10-K for 2025, filed 2026-02-24
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.